Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 3/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14402446 | 1.00 | ALDH1A1 (0.43) | ALDH1A1KMT2ACYP1A2METAP2REN | |
| SCHEMBL6985349 | 0.98 | ALDH1A1 (0.41) | ALDH1A1KMT2ACYP1A2METAP2REN | |
| SCHEMBL14402433 | 0.93 | ALDH1A1 (0.38) | ALDH1A1KMT2ACYP1A2METAP2REN | |
| SCHEMBL13849949 | 0.93 | ALDH1A1 (0.38) | ALDH1A1KMT2ACYP1A2METAP2REN | |
| SCHEMBL14327356 | 0.89 | — | — | |
| SCHEMBL6866119 | 0.88 | ALDH1A1 (0.51) | ALDH1A1KMT2ACYP1A2METAP2REN | |
| SCHEMBL24108682 | 0.84 | ALDH1A1 (0.59) | ALDH1A1KMT2ACYP1A2METAP2 | |
| SCHEMBL8829754 | 0.84 | ALDH1A1 (0.59) | ALDH1A1KMT2ACYP1A2METAP2 | |
| SCHEMBL6662787 | 0.82 | SHBG (0.41) | ALDH1A1KMT2ACYP1A2METAP2REN | |
| SCHEMBL6145227 | 0.82 | SHBG (0.41) | ALDH1A1KMT2ACYP1A2METAP2REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1847533-B1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-7531533-B2 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| EP-1847533-A1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-03-15 | — | — | US | disclosed |
| EP-1268434-A1 | CYCLIC LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001074784-A1 | CYCLIC LACTAMS AS INHIBITORS OF A-β PROTEIN PRODUCTION | DUPONT PHARMACEUTICALS COMPANY (US) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | WNT1, CYP11B2, CYP11B1 | ALDH1A1 1638/4885KMT2A 4051/4885CYP1A2 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.